SG10201605629VA - Antibody targeting through a modular recognition domain - Google Patents

Antibody targeting through a modular recognition domain

Info

Publication number
SG10201605629VA
SG10201605629VA SG10201605629VA SG10201605629VA SG10201605629VA SG 10201605629V A SG10201605629V A SG 10201605629VA SG 10201605629V A SG10201605629V A SG 10201605629VA SG 10201605629V A SG10201605629V A SG 10201605629VA SG 10201605629V A SG10201605629V A SG 10201605629VA
Authority
SG
Singapore
Prior art keywords
recognition domain
antibody targeting
modular recognition
modular
targeting
Prior art date
Application number
SG10201605629VA
Inventor
Iii Carlos F Barbas
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of SG10201605629VA publication Critical patent/SG10201605629VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Mycology (AREA)
SG10201605629VA 2008-01-03 2008-12-24 Antibody targeting through a modular recognition domain SG10201605629VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1881608P 2008-01-03 2008-01-03
US2276708P 2008-01-22 2008-01-22

Publications (1)

Publication Number Publication Date
SG10201605629VA true SG10201605629VA (en) 2016-08-30

Family

ID=40853673

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2013026802A SG189769A1 (en) 2008-01-03 2008-12-24 Antibody targeting through a modular recognition domain
SG10201605629VA SG10201605629VA (en) 2008-01-03 2008-12-24 Antibody targeting through a modular recognition domain

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2013026802A SG189769A1 (en) 2008-01-03 2008-12-24 Antibody targeting through a modular recognition domain

Country Status (18)

Country Link
US (3) US20110189206A1 (en)
EP (2) EP2769991B1 (en)
JP (3) JP5774851B2 (en)
KR (1) KR101658247B1 (en)
CN (3) CN115043946A (en)
AU (1) AU2008346734A1 (en)
BR (1) BRPI0821906B1 (en)
CA (1) CA2711256C (en)
DK (1) DK2769991T3 (en)
EA (2) EA201500156A3 (en)
ES (1) ES2689274T3 (en)
GE (1) GEP20156390B (en)
IL (3) IL206602A0 (en)
MX (1) MX2010007357A (en)
NZ (1) NZ586701A (en)
SG (2) SG189769A1 (en)
WO (1) WO2009088805A2 (en)
ZA (1) ZA201004730B (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2769991T3 (en) 2008-01-03 2018-12-10 Scripps Research Inst ANTIBODY TARGETING WITH A MODULAR RECOGNITION AREA
US8557243B2 (en) * 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8557242B2 (en) * 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8574577B2 (en) * 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8293714B2 (en) * 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
AU2010215761B2 (en) 2009-02-23 2017-04-06 Cytomx Therapeutics, Inc Proproteins and methods of use thereof
EP2258719A1 (en) * 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
WO2011044133A2 (en) * 2009-10-05 2011-04-14 Opsonic Therapeutics Inc. High affinity adaptor molecules for redirecting antibody specifity
CA2804185C (en) 2010-07-12 2017-03-21 Covx Technologies Ireland Limited Multifunctional antibody conjugates
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
US8728473B2 (en) 2010-12-01 2014-05-20 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US20120189633A1 (en) 2011-01-26 2012-07-26 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
EP2673297A2 (en) * 2011-02-11 2013-12-18 Zyngenia, Inc. Monovalent and multivalent multispecific complexes and uses thereof
AU2012258637B2 (en) * 2011-05-24 2017-07-20 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
KR102268351B1 (en) 2012-07-25 2021-06-22 셀덱스 쎄라퓨틱스, 인크. Anti-kit antibodies and uses thereof
JOP20140087B1 (en) 2013-03-13 2021-08-17 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
BR112015023752B1 (en) 2013-03-15 2023-11-14 Zyngenia, Inc. MODULAR RECOGNITION DOMAIN (MRD), COMPLEX COMPRISING MRD AND CETUXIMAB, USES OF THE COMPLEX TO INHIBIT ANGIOGENESIS AND TREAT CANCER AND PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPLEX
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
GB201308745D0 (en) * 2013-05-15 2013-06-26 Imp Innovations Bacteriophage
KR101551299B1 (en) * 2013-05-23 2015-09-10 아주대학교산학협력단 Neuropilin specific tumor penetrating peptide and fusion protein fused with the same
KR102357906B1 (en) 2013-11-27 2022-02-03 자임워크스 인코포레이티드 Bispecific antigen-binding constructs targeting her2
SG11201605093VA (en) 2013-12-23 2016-07-28 Zymeworks Inc Antibodies comprising c-terminal light chain polypeptide extensions and conjugates and methods of use thereof
KR101602870B1 (en) 2014-07-22 2016-03-21 아주대학교산학협력단 Method for Cell-penetrating and cytosol-localizing of intact immunoglobulin antibody, and use thereof
KR101602876B1 (en) 2014-07-22 2016-03-11 아주대학교산학협력단 Method for inhibiting activated RAS using intact immunoglobulin antibody having Cell-penetrating ability and use thereof
WO2017030370A1 (en) 2015-08-17 2017-02-23 서울대학교산학협력단 Chimeric antibody receptor to which anti-cotinine antibody is linked, and use thereof
CN108602870A (en) 2015-12-04 2018-09-28 诺华股份有限公司 Antibody cytokine grafts composition and is used for immunoregulatory method
CA3025757A1 (en) 2016-05-27 2017-11-30 Orum Therapeutics Inc. Cytosol-penetrating antibody and use thereof
EP3496742A4 (en) * 2016-12-01 2020-04-08 University Of South Florida Peptibodies, compositions thereof, and methods of treating atrial fibrillation
EP3567101A4 (en) * 2017-01-05 2020-12-02 Korea Research Institute of Bioscience and Biotechnology Natural killer cell expressing anti-cotinine chimeric antigen receptor
TWI787230B (en) 2017-01-20 2022-12-21 法商賽諾菲公司 Anti-tgf-beta antibodies and their use
TWI788321B (en) * 2017-01-20 2023-01-01 美商健臻公司 Bone-targeting antibodies
KR20200010468A (en) 2017-05-24 2020-01-30 노파르티스 아게 Antibody-Cytokine Implanted Proteins and Methods of Use in Cancer Treatment
JOP20190271A1 (en) 2017-05-24 2019-11-21 Novartis Ag Antibody-cytokine engrafted proteins and methods of use for immune related disorders
US11597736B2 (en) 2017-07-14 2023-03-07 Mitsui Chemicals, Inc. Lithium boron fluorophosphate complex compound, lithium boron fluorophosphate-containing composition, lithium boron fluorophosphate, additive for lithium secondary battery, non-aqueous electrolytic solution for battery, and lithium secondary battery
US20210221849A1 (en) 2018-05-10 2021-07-22 Mirabiologics Inc. Artificial Protein Containing Antigen-Binding Region of Antibody and Being Fused With Physiologically Active Peptide
US10787487B2 (en) 2018-06-21 2020-09-29 Orum Therapeutics Inc. Cell/tissue-specific cell-penetrating antibodies
EP3863672A4 (en) * 2018-10-11 2022-06-29 The Scripps Research Institute Antibody compounds with reactive arginine and related antibody drug conjugates
JP7317343B2 (en) * 2019-03-20 2023-07-31 公立大学法人大阪 Preventive or therapeutic agent for breast cancer and agent for suppressing proliferation of breast cancer cells

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
ES2052027T5 (en) 1988-11-11 2005-04-16 Medical Research Council IMMUNOGLOBULINE VARIABLE DOMAIN SEQUENCE CLONING.
US5196193A (en) * 1989-10-31 1993-03-23 Ophidian Pharmaceuticals, Inc. Antivenoms and methods for making antivenoms
ATE255131T1 (en) * 1991-06-14 2003-12-15 Genentech Inc HUMANIZED HEREGULIN ANTIBODIES
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6025165A (en) 1991-11-25 2000-02-15 Enzon, Inc. Methods for producing multivalent antigen-binding proteins
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
CA2145278C (en) 1992-09-25 2009-03-10 Peter J. Hudson Target binding polypeptide
US6733752B1 (en) 1994-03-30 2004-05-11 The Trustees Of The University Of Pennsylvania Prevention of tumors with monoclonal antibodies against neu
DK0749325T3 (en) 1994-03-07 2002-10-07 Medarex Inc Bispecific molecules with clinical application
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US7063840B2 (en) 1994-10-07 2006-06-20 Regeneron Pharmaceuticals, Inc. TIE-2 ligands, methods of making and uses thereof
EP2258726A1 (en) 1995-06-14 2010-12-08 The Regents of the University of California High affinity human antibodies to c-erbB-2
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6194177B1 (en) 1996-02-20 2001-02-27 Applied Research Systems Ars Holding N.V. DNA encoding a hybrid heterodimeric protein
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
WO1998050431A2 (en) 1997-05-02 1998-11-12 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6207805B1 (en) 1997-07-18 2001-03-27 University Of Iowa Research Foundation Prostate cell surface antigen-specific antibodies
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
BRPI9910332B8 (en) 1998-05-06 2021-05-25 Genentech Inc method for purifying a polypeptide from a composition
US6875741B2 (en) 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
IL141877A0 (en) * 1998-09-14 2002-03-10 Biogen Inc Pharmaceutical compositions containing alpha4 integrin antagonists
CZ303155B6 (en) 1999-02-12 2012-05-09 The Scripps Research Institute Therapeutic composition for treating tumor cell in a tumor or tumor metastases and a kit comprising thereof
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US6268488B1 (en) 1999-05-25 2001-07-31 Barbas, Iii Carlos F. Prodrug activation using catalytic antibodies
AU783960B2 (en) 1999-06-07 2006-01-05 Immunex Corporation Tek antagonists
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
BRPI0012198B8 (en) 1999-06-25 2021-05-25 Genentech Inc humanized antibodies, composition and immunoconjugate
IL147017A0 (en) 1999-06-25 2002-08-14 Genentech Inc TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES
CN100443118C (en) 1999-08-27 2008-12-17 杰南技术公司 Dosages for treatment with anti-ErbB2 antibodies
US6497909B1 (en) 1999-09-09 2002-12-24 General Mills, Inc. Method of bleaching cereal grain
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
ES2528794T3 (en) 2000-04-11 2015-02-12 Genentech, Inc. Multivalent antibodies and uses thereof
JP2003530871A (en) 2000-04-21 2003-10-21 アムジエン・インコーポレーテツド Integrin / adhesion factor antagonist
WO2001089566A1 (en) 2000-05-19 2001-11-29 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
PL206142B1 (en) 2001-01-09 2010-07-30 Merck Patent Gmbhmerck Patent Gmbh Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
BR0207267A (en) * 2001-02-19 2004-02-10 Merck Patent Gmbh Artificial proteins with reduced immunogenicity
DK1366067T3 (en) * 2001-03-07 2012-10-22 Merck Patent Gmbh EXPRESSION TECHNOLOGY FOR PROTEINS CONTAINING A HYBRID ISOTYPE ANTIBODY UNIT
IL145035A0 (en) 2001-08-21 2002-06-30 Yeda Res & Dev Molecular linkers suitable for crystallization and structural analysis of molecules of interest and method of using same
JP3798285B2 (en) * 2001-10-02 2006-07-19 富士通株式会社 Network topology collection device
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7736652B2 (en) * 2002-03-21 2010-06-15 The Regents Of The University Of California Antibody fusion proteins: effective adjuvants of protein vaccination
US7332585B2 (en) * 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US20070003514A1 (en) 2002-04-05 2007-01-04 The Regents Of The University Of California Mono-and bi-functional antibody conjugates as effective adjuvants of protein vaccination
IL149820A0 (en) * 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
ATE328906T1 (en) 2002-06-28 2006-06-15 Domantis Ltd DUAL-SPECIFIC LIGANDS WITH INCREASED HALF-LIFE
US20070104710A1 (en) 2002-06-28 2007-05-10 Domants Limited Ligand that has binding specificity for IL-4 and/or IL-13
WO2006028429A2 (en) * 2002-08-05 2006-03-16 The Johns Hopkins University Peptides for targeting the prostate specific membrane antigen
US20040057969A1 (en) 2002-09-20 2004-03-25 Smith Mark L Compositions containing stabilized hepatitis antigen and methods of their use
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
US7541440B2 (en) 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
EP1572131B1 (en) 2002-10-08 2016-07-06 Immunomedics, Inc. Antibody therapy
HUE025086T2 (en) * 2002-10-10 2016-02-29 Merck Patent Gmbh Pharmaceutical compositions directed to erb-b1 receptors
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
JP4733635B2 (en) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド Anti-CD19 antibody
GB0320878D0 (en) 2003-09-05 2003-10-08 Celltech R&D Ltd A protein involved in carcinoma
US20070086998A1 (en) 2003-09-09 2007-04-19 Gpc Biotech Ag Therapeutic human anti-mhc class II antibodies and their uses
US20050136044A1 (en) * 2003-12-04 2005-06-23 Watkins Jeffry D. Butyrylcholinesterase variants that alter the activity of chemotherapeutic agents
ES2364147T3 (en) 2004-01-16 2011-08-25 Regeneron Pharmaceuticals, Inc. FUSION POLIPEPTIDES CAPABLE OF ACTIVATING RECEPTORS.
CA2559719A1 (en) * 2004-03-17 2005-09-29 University Of Hawaii Sensor constructs and detection methods
US7598350B2 (en) * 2004-03-19 2009-10-06 Imclone Llc Human anti-epidermal growth factor receptor antibody
CA2565827A1 (en) 2004-05-05 2005-12-15 Merrimack Pharmaceuticals, Inc. Bispecific binding agents for modulating biological activity
JP2008532476A (en) 2004-08-12 2008-08-21 ダイアックス コーポレーション Complex binding protein
US7442778B2 (en) 2004-09-24 2008-10-28 Amgen Inc. Modified Fc molecules
WO2007001457A2 (en) 2004-11-12 2007-01-04 Xencor, Inc. Antibodies operably linked to selected chemoattractants
JP2008523083A (en) 2004-12-08 2008-07-03 イムノメディクス， インコーポレイテッド Methods and compositions for immunotherapy and detection of inflammatory and immune dysregulated diseases, infectious diseases, pathological angiogenesis and cancer
ES2371083T3 (en) 2004-12-21 2011-12-27 Medimmune Limited ANTIBODIES DIRECTED AGAINST ANGIOPOYETINA-2 AND USES OF THE SAME.
KR101404512B1 (en) * 2005-01-05 2015-01-29 에프-스타 비오테크놀로기쉐 포르슝스 운드 엔트비클룽스게스.엠.베.하. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
AR050418A1 (en) 2005-01-21 2006-10-25 Genentech Inc HER ANTIBODY FIXED DOSAGE
BRPI0519897A2 (en) 2005-02-23 2009-08-18 Merrimack Pharmaceuticals Inc method for modulating the biological activity or activities of target molecules in a target cell, bispecific binding agent, composition, use of a bispecific binding agent, and kit
BRPI0614100A2 (en) 2005-08-03 2011-03-09 Immunogen Inc liquid immunoconjugate formulations
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5364870B2 (en) 2005-08-19 2013-12-11 アッヴィ・インコーポレイテッド Dual variable domain immunoglobulins and uses thereof
US20090226466A1 (en) * 2005-11-03 2009-09-10 Sherman Fong Therapeutic anti-her2 antibody fusion polypeptides
EP1790358A1 (en) 2005-11-23 2007-05-30 Université de Reims Champagne-Ardennes Protein constructs designed for targeting and lysis of cells
GB0524788D0 (en) * 2005-12-05 2006-01-11 Affibody Ab Polypeptides
EA013878B1 (en) 2005-12-06 2010-08-30 Домантис Лимитед Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
US20100021473A1 (en) 2005-12-06 2010-01-28 Domantis Limited Bispecific Ligands With Binding Specificity to Cell Surface Targets and Methods of Use Therefor
AU2006324477A1 (en) 2005-12-15 2007-06-21 Medimmune Limited Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or Flt1 antagonist for treating cancer
CN103242451B (en) 2005-12-16 2017-11-21 Ibc医药公司 Multivalence bioactive assemblies based on immunoglobulin
US20100266620A1 (en) 2006-01-20 2010-10-21 Le Sun Immunoconjugates for treatment of infectious diseases
AR059066A1 (en) 2006-01-27 2008-03-12 Amgen Inc COMBINATIONS OF THE ANGIOPOYETINE INHIBITOR -2 (ANG2) AND THE VASCULAR ENDOTELIAL GROWTH FACTOR INHIBITOR (VEGF)
CA2640671A1 (en) 2006-02-02 2007-11-29 The General Hospital Corporation Engineered antibody-stress protein fusions
EP1820513A1 (en) 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
US7456016B2 (en) * 2006-02-24 2008-11-25 Arius Research Inc. Cancerous disease modifying antibodies
US20100021379A1 (en) 2006-06-29 2010-01-28 The Regents Of The University Of California Chemical Antibodies for Immunotherapy and Imaging
AT503889B1 (en) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F MULTIVALENT IMMUNE LOBULINE
CN101522717A (en) 2006-08-04 2009-09-02 阿斯利康(瑞典)有限公司 Antibodies to erbb2
US20100297103A1 (en) 2006-09-14 2010-11-25 Medical & Biological Laboratories Co., Ltd. Antibody having enhanced adcc activity and method for production thereof
PT2076290T (en) 2006-10-27 2017-01-17 Sunnybrook Health Sciences Center Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis
US20100166746A1 (en) 2006-12-04 2010-07-01 Medlmmune Way High potency recombinant antibodies, methods for producing them and use in cancer therapy
AU2007343610C1 (en) 2007-01-17 2013-11-07 Immunomedics, Inc. Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
EP2114985B1 (en) 2007-02-02 2014-12-17 Baylor Research Institute Multivariable antigens complexed with targeting humanized monoclonal antibody
US10259860B2 (en) 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
MX2009008981A (en) 2007-03-02 2009-09-02 Genentech Inc Predicting response to a her inhibitor.
WO2008116293A1 (en) 2007-03-23 2008-10-02 The Governors Of The University Of Alberta Multivalent heterobifunctional polymers and methods of their use
EP2160200B1 (en) 2007-05-14 2013-07-10 The University of Chicago Antibody-LIGHT fusion products as cancer therapeutics
AU2008282218A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
MX2010005927A (en) 2007-11-30 2010-06-15 Glaxo Group Ltd Antigen-binding constructs.
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US20140127200A1 (en) 2008-01-03 2014-05-08 The Scripps Research Institute Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains
DK2769991T3 (en) 2008-01-03 2018-12-10 Scripps Research Inst ANTIBODY TARGETING WITH A MODULAR RECOGNITION AREA
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
AU2009209251B8 (en) 2008-01-28 2015-03-26 Medimmune Limited Stabilized Angiopoietin-2 antibodies and uses thereof
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
US20110076723A1 (en) 2008-05-23 2011-03-31 Samsung Electronics Co., Ltd. Antibody-peptide fused synergibody
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
EP2315775A2 (en) 2008-07-21 2011-05-04 Compugen Ltd. Angiopoietin derived peptides
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
WO2010066836A2 (en) 2008-12-10 2010-06-17 Ablynx Nv Amino acid sequences directed against the angiopoietin/tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
MX2011009797A (en) 2009-03-20 2012-01-12 Amgen Inc Selective and potent peptide inhibitors of kv1.3.
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
JO3182B1 (en) 2009-07-29 2018-03-08 Regeneron Pharma High Affinity Human Antibodies to Human Angiopoietin-2
KR101688522B1 (en) 2009-12-15 2016-12-21 삼성전자주식회사 Angiopoietin-2 specific antibodies and uses thereof
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
AU2012258637B2 (en) 2011-05-24 2017-07-20 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
BR112015023752B1 (en) 2013-03-15 2023-11-14 Zyngenia, Inc. MODULAR RECOGNITION DOMAIN (MRD), COMPLEX COMPRISING MRD AND CETUXIMAB, USES OF THE COMPLEX TO INHIBIT ANGIOGENESIS AND TREAT CANCER AND PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPLEX

Also Published As

Publication number Publication date
EP2769991A1 (en) 2014-08-27
IL223647A0 (en) 2013-02-03
MX2010007357A (en) 2011-03-03
IL248905A0 (en) 2017-01-31
SG189769A1 (en) 2013-05-31
US20130195860A1 (en) 2013-08-01
WO2009088805A3 (en) 2009-12-30
EP2769991B1 (en) 2018-08-22
US20110189206A1 (en) 2011-08-04
CN115043946A (en) 2022-09-13
ES2689274T3 (en) 2018-11-13
CN101965406A (en) 2011-02-02
BRPI0821906A2 (en) 2014-11-04
WO2009088805A2 (en) 2009-07-16
JP2015227345A (en) 2015-12-17
EP2237797A2 (en) 2010-10-13
EA021967B1 (en) 2015-10-30
KR101658247B1 (en) 2016-09-22
EA201500156A2 (en) 2017-07-31
EA201500156A3 (en) 2017-09-29
BRPI0821906B1 (en) 2022-06-07
AU2008346734A1 (en) 2009-07-16
EP2237797A4 (en) 2012-11-07
CN108864285A (en) 2018-11-23
IL206602A0 (en) 2010-12-30
CA2711256C (en) 2019-01-15
JP5774851B2 (en) 2015-09-09
NZ586701A (en) 2013-07-26
CA2711256A1 (en) 2009-07-16
JP2018015002A (en) 2018-02-01
JP2011509084A (en) 2011-03-24
ZA201004730B (en) 2013-10-30
DK2769991T3 (en) 2018-12-10
US20160159863A1 (en) 2016-06-09
US10030051B2 (en) 2018-07-24
EA201070822A1 (en) 2011-02-28
GEP20156390B (en) 2015-11-10
KR20100115352A (en) 2010-10-27

Similar Documents

Publication Publication Date Title
IL248905A0 (en) Antibody targeting through a modular recognition domain
EP2344958A4 (en) Image-based semantic distance
IL211180B (en) Peg-docetaxel conjugates
EP3064512C0 (en) Anti-cldn6 antibody
ZA201102119B (en) Improved antibody libraies
EP2271359C0 (en) Camptothecin-binding moiety conjugates
ZA201101639B (en) A crutch
GB0812538D0 (en) A Carton
EP1987064A4 (en) Domain antibody construct
EP2329632A4 (en) Hiding a device identity
EP2246120A4 (en) Electrostatic atomizer
PL2291315T3 (en) Securing element for a closing element
EP2340752A4 (en) A bread-toaster
EP2251092A4 (en) Electrostatic atomizer
GB0908606D0 (en) A stereo-endoscope
GB0906896D0 (en) A potty
EP2318436A4 (en) Variant domain antibodies
EP2249132A4 (en) Flowmeter
GB0922260D0 (en) A pipe-liner
EP2358251A4 (en) A dustcup
GB0900327D0 (en) A paving aid
ES1070427Y (en) DRINK DRINK DISPENSER
GB2458284B (en) A button-cuff
GB0911770D0 (en) Antibody
GB0807279D0 (en) A half pipe